ABT vs SARO · P/E 25, rev $44.33B vs P/E 31, rev $6.06B
Abbott Laboratories (ABT) versus StandardAero, Inc. (SARO) — a side-by-side from cached financials, not a winner call.
Abbott Laboratories (ABT) is a medical devices company listed on NYSE.
StandardAero, Inc. (SARO) is a aerospace & defense company listed on NYSE.
Latest reported ABT revenue for 2025-12-31 was $44.33B. Net income was $6.52B. Revenue was up 5.7% from 2024-12-31 to 2025-12-31. ABT currently screens at market cap $154.15B and trailing P/E 24.8.
Latest reported SARO revenue for 2025-12-31 was $6.06B. Net income was $277.4M. Revenue was up 15.8% from 2024-12-31 to 2025-12-31. SARO currently screens at market cap $9.03B and trailing P/E 30.9.
ABT currently screens at market cap $154.15B and trailing P/E 24.8. SARO currently screens at market cap $9.03B and trailing P/E 30.9.
Not investment advice. Open the ABT and SARO stock pages for the full models.
Not investment advice.